Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies reported third-quarter 2026 revenue of $83.9 million, above analyst expectations, and achieved company-wide profitability with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million. Core MRD revenue rose 44% excluding milestones, while clonoSEQ test volume increased 46% year over year to 39,587. The company raised its 2026 MRD revenue guidance to $276 million–$286 million from $268 million–$278 million. It also submitted a technical assessment to MolDX seeking a new Medicare bundle for multiple myeloma maintenance testing.